Journal Article10.1016/J.PNPBP.2007.03.005
Bipolar disorder: how far are we from a rigorous definition and effective management?
37
TL;DR: The development of a specific depression rating scale will improve the assessment of bipolar depression in both research and clinical settings and improve the development of better treatments and interventions.
read more
Abstract: Bipolar disorder is a pathological disturbance of mood, characterized by waxing and waning manic, depressive and, sometimes distinctly mixed states. A diagnosis of bipolar disorder can only be made with certainty when the manic syndrome declares itself. Most individuals who are diagnosed with this disorder will experience both poles of the illness recurrently, but depressive episodes are the commonest cause of morbidity and, indeed, of death by suicide. Twin, adoption and epidemiological studies suggest a strongly genetic aetiology. It is a genetically and phenotypically complex disorder. Thus, the genes contributing are likely to be numerous and of small effect. Individuals with bipolar disorder also display deficits on a range of neuropsychological tasks in both the acute and euthymic phases of illness and correlations between number of affective episodes experienced and task performance are commonly reported. Current self-report and observer-rated scales are optimized for unipolar depression and hence limited in their ability to accurately assess bipolar depression. The development of a specific depression rating scale will improve the assessment of bipolar depression in both research and clinical settings. It will improve the development of better treatments and interventions. Guidelines support the use of antidepressants for bipolar depression. With regard to the adverse effects of antidepressants for bipolar depression, double-blind, placebo-controlled data suggest that antidepressant monotherapy or the addition of a tricyclic antidepressant may worsen the course of bipolar disorder. Importantly, adjunctive psychotherapies add significantly (both statistically and clinically) to the efficacy of pharmacological treatment regimens. The successful management of bipolar disorder clearly demands improved recognition of bipolar disorder and effective long-term treatment for bipolar depression as well as mania.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Modelling the anxiety-depression continuum in chicks
TL;DR: The model is characterized as a simulation of the anxiety-depression continuum and begin to establish the paradigm as a high-utility adjuvant to rodent screening assays for putative anxiolytic and antidepressant compounds.
46
Treatment of bipolar disorder: new perspectives.
TL;DR: Cognitive deficits, persistence of residual symptoms, and increased mortality of BD are recognized as important for outcome of BD, yet are not always adequately addressed by traditional treatments.
32
Psychopharmacological drug utilization patterns in pregnant women with bipolar disorder - A nationwide register-based study.
TL;DR: There was a decrease in the proportion of women redeeming prescriptions during pregnancy and there was a high prevalence of antidepressant use without a mood-stabilizer, potentially putting women at risk for a switch to mania - although this is still debated.
27
The supra-additive hyperactivity caused by an amphetamine-chlordiazepoxide mixture exhibits an inverted-U dose response: negative implications for the use of a model in screening for mood stabilizers.
Michy P. Kelly,Sheree F. Logue,Jason M. Dwyer,Chad E. Beyer,Heather Majchrowski,Zhang Cai,Zhi Liu,Adedayo Adedoyin,Sharon Rosenzweig-Lipson,Thomas A. Comery +9 more
TL;DR: It is argued that the data here challenge the utility of the AMPH-CDP mixture model in drug discovery and show that the prototypical mood stabilizer valproic acid augments the effects of CDP on hypolocomotion and anxiolytic-like behavior.
25
Auditory processing deficits in bipolar disorder with and without a history of psychotic features.
R Zenisek,Nicholas S. Thaler,Griffin P. Sutton,Erik N. Ringdahl,Joel S. Snyder,Daniel N. Allen +5 more
TL;DR: Auditory perception deficits have been identified in schizophrenia (SZ) and linked to dysfunction in the auditory cortex and it may be that individuals with BD who also exhibit psychotic symptoms demonstrate a similar impairment in auditory perception.
15
References
A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression
Joseph R. Calabrese,Charles L. Bowden,Gary S. Sachs,John A. Ascher,Eileen Monaghan,G. David Rudd +5 more
TL;DR: In this article, the first controlled multicenter study evaluating lamotrigine monotherapy in the treatment of bipolar I depression was conducted, where outpatients with bipolar I disorder experiencing a major depressive episode (DSM-IV) or placebo as monotherapy for 7 weeks.
934
Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression
Mauricio Tohen,Mauricio Tohen,Eduard Vieta,Joseph R. Calabrese,Terence A. Ketter,Gary S. Sachs,Charles L. Bowden,Philip B. Mitchell,Franca Centorrino,R.C. Risser,Robert W. Baker,Angela R. Evans,Karin Beymer,Sanjay Dubé,Sanjay Dubé,Gary D. Tollefson,Alan Breier +16 more
TL;DR: Olanzapine is more effective than placebo, and combined olanzapine-fluoxetine isMore effective than olanZapine and placebo in the treatment of bipolar I depression without increased risk of developing manic symptoms.
907
A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in the Treatment of Bipolar I or II Depression
Joseph R. Calabrese,Paul E. Keck,Wayne Macfadden,Margaret Minkwitz,Terence A. Ketter,Richard H. Weisler,Andrew J. Cutler,Robin Mccoy,Ellis Wilson,Jamie Mullen +9 more
TL;DR: Quetiapine monotherapy is efficacious and well tolerated for the treatment of bipolar depression and demonstrated statistically significant improvement in Montgomery-Asberg Depression Rating Scale total scores compared with placebo from week 1 onward.
852
Heritability Estimates for Psychotic Disorders: The Maudsley Twin Psychosis Series
Alastair G. Cardno,E. Jane Marshall,Bina Coid,Alison Macdonald,T Ribchester,N Davies,P. Venturi,Lisa Jones,Shôn Lewis,Pak C. Sham,Irving I. Gottesman,Anne Farmer,Peter McGuffin,A.M. Reveley,Robin M. Murray +14 more
TL;DR: A substantial genetic contribution to variance in liability was confirmed for the major diagnostic categories except Research Diagnostic Criteria depressive psychosis and unspecified functional psychosis, where familial transmission was confirmed, but the relative contribution of genetic and common environmental factors was unclear.
847
The emerging epidemiology of hypomania and bipolar II disorder.
TL;DR: The study suggests that recurrent brief hypomania belongs to the bipolar spectrum and should be verified on larger national cohorts in other epidemiological and clinical studies.
789